Skip to main content
Clinical Trials/NCT01713478
NCT01713478CompletedNot Applicable

An Integrated Approach of Subclinical Myocardial Dysfunction in Patients With Hepatic Cirrhosis: Echocardiography, Specific Biomarkers, and Vascular Assessment

Carol Davila University of Medicine and Pharmacy1 site in 1 country100 target enrollmentStarted: December 1, 2011Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
100
Locations
1
Primary Endpoint
Subclinical Myocardial Dysfunction

Study Overview

Brief Summary

The prevalence of hepatic cirrhosis in Romania is very high, with a 10-year mortality of 34-66%. Upward trend of mortality is observed. It is known that cirrhosis is associated with cardiac abnormalities. These can induce several complications of cirrhosis, and increase postoperative mortality. Therefore, it is a major public health issue and research in this field should be a priority.

Few studies evaluated the cardiac function in cirrhotic patients, using only conventional echocardiography. However, this allows only the late diagnosis of cardiac dysfunction, which might be already irreversible. Consequently, description of new parameters, which could detect early dysfunction, becomes essential. There is no study designed to estimate intrinsic myocardial properties in cirrhosis. New methods (Tissue Doppler and Speckle-tracking echocardiography) could be essential to detect early cardiac dysfunction. The exact role of biological markers in the diagnosis of cardiac dysfunction remains to be clarified. Impaired cardiac function coupled with augmented vascular function could be the model for cirrhotic patients. This type of ventriculo-arterial interaction has never been described.

The main objectives of our project are:

  1. to investigate the mechanisms which lead to cardiac dysfunction;
  2. to describe new parameters for the early diagnosis of cirrhotic cardiomyopathy;
  3. to describe the type of ventriculo-arterial interaction;
  4. the association between biological markers and echo parameters.

Detailed Description

Scientific context and motivation:

Cirrhosis is the end stage of chronic damage to the liver. The prevalence is estimated to be very high in Romania, more than 1000/100.000 inhabitants, with 10-year mortality of 34-66%. Upward trends of mortality are observed in a few countries, including Romania, which had extremely high mortality rates. The cost in terms of hospital costs and lost productivity is high. Therefore, hepatic cirrhosis represents a major public health in Romania.

It is known that hepatic cirrhosis is associated with cardiovascular abnormalities. These abnormalities have been suggested to induce/aggravate several complications of cirrhosis, and also to increase postoperative mortality after major surgery or liver transplantation. Few studies documented the existence of a hyperdynamic circulation, with increased cardiac output and reduced systemic vascular resistance. Despite this hyperkinetic circulation, some patients have abnormal ventricular function unmasked by physiologic/pharmacologic stress.

There are few studies of cardiac function in cirrhosis, although contractile function disorders found in nonalcoholic cirrhosis in animal models suggested that this is independent from alcohol intake. These issues are complicated by the fact that, alcohol use represents one of the commonest causes of both cirrhosis and cardiomyopathy. There are reasons to believe that cirrhosis per se may be associated with subtle contractile dysfunction. First, hyperkinetic circulatory changes may induce a high-output cardiac failure resembling a chronic volume overload of the heart. Second, cirrhosis is associated with high serum catecholamine levels, and long-term exposure to elevated catecholamines results in cardiomyopathy. Third, necropsy series of patients with alcoholic/nonalcoholic cirrhosis show similar cardiac pathologic findings: diffuse fibrosis, subendocardial edema, nuclear and cytoplasmic vacuolation.

Despite the increased cardiac output, ventricular inotropic and chronotropic responses to stimuli are blunted, a condition known as "cirrhotic cardiomyopathy". These include systolic and diastolic dysfunction, electrophysiological changes, and structural changes. There are no clear consensus definition for this condition. Cardiac function was evaluated by classic echocardiography, 2D and color/spectral Doppler: cardiac dimensions, left ventricular ejection fraction (LVEF), systolic and diastolic timings. All of these changes are dependent on load conditions, and cirrhosis has major variability of preload conditions. However, these conventional measurements allow only the late diagnosis of cardiac dysfunction, which might be already irreversible.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
18 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Patients with certified diagnosis of hepatic cirrhosis;
  • •Age over 18 years;
  • •Informed consent signed;
  • •Sinus rhythm;
  • •Ejection fraction > 50%

Exclusion Criteria

  • •Any history of cardiovascular disease/active cardiovascular treatment(βblockers used for prevention of the variceal hemorrhage will be stopped 24h before the evaluation);
  • •Diabetes mellitus;
  • •Chronic diseases/neoplasia with estimated survival time under 6 months;
  • •Pulmonary diseases that could affect cardiac function;
  • •Other etiology of cirrhosis that could affect cardiac function: Wilson disease, hemochromatosis, glycogen storage diseases;
  • •Encephalopathy over grade 2/ascitis without medical control;
  • •Inappropriate quality of echocardiographic images.

Arms & Interventions

cirrhotic patients

Experimental

Study will include 50 cirrhotic patients, divided in 2 subgroups: 25 with alcoholic cirrhosis, and 25 with viral cirrhosis

  1. Routine blood samples
  2. Electrocardiogram (12 leads)
  3. Specific biomarkers: proBNP, troponin, myocardial fibrosis (β cross laps and procollagen type-1 amino terminal), and markers of inflammation (PCR-hs, IL1, IL6, IL 10, TNFα); oxidative stress: carbonyl in plasmatic proteins, and the antioxidant capacity of plasma.
  4. Comprehensive Echocardiography

Intervention: echocardiography (Other)

normal controls

Active Comparator

50 normals subjects with the same procedures as cirrhotic patients: echocardiography, ECG, biomarkers

Intervention: echocardiography (Other)

Outcomes

Primary Outcomes

Subclinical Myocardial Dysfunction

Time Frame: Baseline

The main objectives are to detect, by new echocardiographic methods, early cardiac dysfunction in cirrhotic patients

Secondary Outcomes

  • Biomarkers(Baseline)

Investigators

Sponsor
Carol Davila University of Medicine and Pharmacy
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Dragos Vinereanu

Professor, MD, PhD, FESC

Carol Davila University of Medicine and Pharmacy

Study Sites (1)

Loading locations...

Similar Trials